Amicus Therapeutics — FY2019 Earnings Presentation
24 slides from Amicus Therapeutics's earnings presentation, Mar 2, 2020
Slide 1: 2019 Financial Results Conference Call & Webcast
2019 Financial Results Conference Call & Webcast March 2, 2020
Slide 2: Forward-Looking Statements
Introduction 2 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinica
Slide 3: A leading fully-integrated, global rare disease biotechnology company
Introduction 3 A leading fully-integrated, global rare disease biotechnology company Gene Therapy World Class PLATFORM BIOLOGICS Protein Engineering Capabilities & Glycobiology AT-GAA EMPLOYEES Phase 3 in Robust R&D in 27 Countries Pompe Disease Engine Nearly 50+ Lysosomal GLOBAL Disorders and More
Slide 4: Key Takeaways
Introduction 4 Key Takeaways Recent successes across our science, clinical, regulatory and commercial efforts position us for the future Galafold Continues AT-GAA for Pompe Portfolio of Gene Strong Financial Strong Launch Advances Toward Therapy Programs Outlook with Current Performance & Approval a
Slide 5: 2020 Key Strategic Priorities
Introduction 5 2020 Key Strategic Priorities 1 Achieve global product revenue for Galafold of $250M-$260M Complete Pompe Phase 3 PROPEL study, enroll pediatric studies 2 and advance manufacturing to support 2021 BLA and MAA Advance clinical development, manufacturing and regulatory 3 discussions for
Slide 6: Galafold (migalastat) Global Launch
Galafold® (migalastat) Global Launch… …taking a leadership role in the treatment of Fabry disease “We push ideas as far and as fast as possible” - Amicus Belief Statement
Slide 7: Galafold: Precision Medicine for Fabry Disease
Galafold: Precision Medicine for Fabry Disease 7 Galafold Snapshot (as of December 31, 2019) Galafold is the cornerstone of Amicus’ success. It is an orally delivered small molecule precision medicine with a unique mechanism of action for Fabry patients with amenable variants that replaces the need
Slide 8: 2019 Galafold Success
Galafold: Precision Medicine for Fabry Disease 8 2019 Galafold Success Strong full-year revenue performance of $182M, exceeding guidance of $170M-$180M Quarterly Galafold Sales Year-over-Year Galafold Sales Growth 60.0 $55M 50.0 $49M -5% $44M 40.0 +105% $34M 30.0 $182M 20.0 $91M 10.0 0.0 1Q19 2Q19 3
Slide 9: Galafold Growth Trajectory
Galafold: Precision Medicine for Fabry Disease 9 Galafold Growth Trajectory Galafold is on track to generate $1B+ in projected cumulative revenues from 2020-2022 and is on an anticipated path to $500M+ in annual sales in 2023 and $1B+ annual sales at peak $500M+ $1B Annual Revenue $250M- $91M $182M
Slide 10: AT-GAA: Next Potential Standard of Care for Pompe Disease
AT-GAA: Next Potential Standard of Care for Pompe Disease “We encourage and embrace constant innovation” - Amicus Belief Statement
Slide 11: FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease
AT-GAA for Pompe Disease 11 U.S. FDA Granted BTD to AT-GAA in Late-Onset Pompe Disease (LOPD) AT-GAA is the first ever second-generation product for any lysosomal disorder to earn FDA Breakthrough Therapy Designation (BTD) AT-GAA BTD Based on Ph 1/2 Clinical Efficacy • Improvements in 6-minute walk
Slide 12: AT-GAA: Key Takeaways
AT-GAA for Pompe Disease 12 AT-GAA: Key Takeaways • PROPEL pivotal study exceeded enrollment with data expected 1H2021 • Breakthrough Therapy Designation and the Promising Innovative Medicine designation highlight unmet need in AT-GAA for Pompe Pompe disease today Advances Toward • Plan to submit an
Slide 13: Financial Summary
Financial Summary “We are business led and science driven” - Amicus Belief Statement
Slide 14: 2019 Select Financial Results
Financial Summary 14 2019 Select Financial Results 2019 revenue of $182M from global Galafold sales Dec. 31, 2019 (in thousands, except per share data) Dec. 31, 2018 Product Revenue $182,237 $91,245 Cost of Goods Sold 21,963 14,404 R&D Expense* 286,378 270,902 SG&A Expense 169,861 127,200 Changes in
Slide 15: Cash Runway Now to Well into 2022
Financial Summary 15 Cash Runway Now to Well into 2022 (~2+ years) Fully funded through major milestones in portfolio and continued global growth $450M+ Well into Cash ~2+ Years Cash Runway 2022 YE2019
Slide 16: Financial Outlook: Key Takeaways
Financial Summary 16 Financial Outlook: Key Takeaways • Company fully funded through major milestones in portfolio and continued global growth • Cumulative Galafold projected revenue of $1B+ in 2020-2022 offsets significant majority of company spend/investments • Extended cash flow runway through Op
Slide 17: Next Generation Gene Therapy Platform
Next Generation Gene Therapy Platform “We have a duty to obsolete our own technologies” - Amicus Belief Statement
Slide 18: Next Generation Gene Therapy Platform pipeline
Next Generation Gene Therapy Platform 18 DISCOVERY PRECLINICAL PHASE 1/2 PHASE 3 REGULATORY COMMERCIAL Fabry Franchise Galafold®(migalastat) Monotherapy ODD Fabry Gene Therapy PENN Pompe Franchise AT-GAA (Novel ERT + Chaperone) ODD Pompe Gene Therapy PENN Batten Franchise – Gene Therapies CLN6 Batte
Slide 19: Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases
Next Generation Gene Therapy Platform 19 Combines Amicus and Penn Expertise Across Lysosomal and Rare Diseases An R&D platform with rights to 50+ diseases, including 8 active preclinical programs Protein Team of 200+ Engineering & scientists bringing Glycobiology expertise and Expertise Next- experi
Slide 20: Gene Therapy: Updates & Key Takeaways
Next Generation Gene Therapy Platform 20 Gene Therapy: Updates & Key Takeaways • CLN6 Phase 1/2 interim data shows profound impact with potential to become first ever approved gene therapy for fatal brain disease in children • Plan to report initial data for patients enrolled in CLN3 Phase 1/2 Portf
Slide 21: Closing Remarks
Closing Remarks “We are business led and science driven” - Amicus Belief Statement
Slide 22: Thank You
Thank You “Our passion for making a difference unites us” -Amicus Belief Statement
Slide 23: Appendix
Appendix Amicus Therapeutics
Slide 24: Appendix Non-GAAP Reconciliation
Appendix 24 Non-GAAP Reconciliation